Suzhou Fuent Pharmaceutical

Suzhou Fuent Pharmaceutical is a clinical-stage biotechnology company and the Chinese subsidiary of US-based Qurgen, Inc. Based in Suzhou, China, the company is a pioneer in regenerative medicine and oncology, utilizing its proprietary QQ-Protein Delivery Technology to deliver transcription factor protein drugs directly into cells. This platform enables the in vivo reprogramming of diseased or damaged tissues into healthy ones, offering a novel cell-converting approach to therapy. Its lead candidate, SON-DP, is currently in Phase 1 clinical trials in both the United States and China for the treatment of various advanced solid tumors, including gastric and liver cancers. The company also maintains a state-of-the-art GMP manufacturing facility in Suzhou to support its expanding global clinical pipeline.